Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | SWOG S1801: 3-year outcomes of neoadjuvant-adjuvant pembrolizumab

Sapna Patel • 17 Oct 2025
ESMO 2025
Melanoma Skin Cancer Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab
SWOG S1801

Sapna Patel, MD, Colorado Cancer Center, Aurora, CO, discusses updated 3-year results from the SWOG S1801 trial (NCT03698019) of neoadjuvant–adjuvant versus adjuvant pembrolizumab in patients with resectable melanoma. With extended follow-up, the event-free survival advantage for the neoadjuvant/adjuvant regimen was maintained, alongside a trend toward improved overall survival. Safety outcomes remained consistent between groups. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sapna Patel

Phase Ia/b trial of IMA203, a PRAME-directed TCR therapy, in uveal melanoma
2:44
Phase Ia/b trial of IMA203, a PRAME-directed TCR therapy, in uveal melanoma
Sapna Patel • 17 Oct 2025
Phase I trial of SX-682, a CXCR1/2 inhibitor, in metastatic melanoma
1:38
Phase I trial of SX-682, a CXCR1/2 inhibitor, in metastatic melanoma
Sapna Patel • 3 Jun 2024
Development of SX-682 and targeting CXCR1 and CXCR2 in melanoma
1:01
Development of SX-682 and targeting CXCR1 and CXCR2 in melanoma
Sapna Patel • 3 Jun 2024
Evaluating the safety of SX-682, a CXCR1/2 inhibitor, with pembrolizumab in melanoma
0:52
Evaluating the safety of SX-682, a CXCR1/2 inhibitor, with pembrolizumab in melanoma
Sapna Patel • 3 Jun 2024

Related Videos

Predictors of toxicity and tolerability with lifileucel in advanced melanoma
1:18
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh • 30 May 2026
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
1:00
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
Alexandra Haugh • 30 May 2026
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
2:41
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
Alexandra Haugh • 30 May 2026
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
1:05
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
James Smithy • 31 May 2026
The content of VJOncology is intended for healthcare professionals